Skip to main content

Table 2 Univariate analysis

From: Subcellular localisation of pMEK has a different prognosis in locally advanced head and neck cancer treated with concomitant radiochemotherapy

 

DFS

OS

Variable

HR (95 % CI)

P value

HR (95 % CI)

P value

Age (<50 vs ≥50)

1.09 (0.60–1.90)

0.70

1.24 (0.73–2.12)

0.43

Oropharynx vs non-oropharynx

1.30 (0.82–2.29)

0.23

1.20 (0.73–2.10)

0.40

T stage (T1/2 vs T3/4)

0.91 (0.43–1.91)

0.79

1.03 (0.47–2.27)

0.98

N stage (0–1 vs 2–3)

2.03 (1.26–3.28)

0.01

2.11 (1.20–3.50)

0.01

ECOG performance status (0 vs ≥1)

1.50 (0.87–2.47)

0.14

1.50 (0.87–2.58)

0.14

P16

1.30 (0.73–2.51)

0.34

1.36 (0.71–2.59)

0.35

Ki-67

0.82 (0.51–1.33)

0.42

0.95 (0.57–1.56)

0.83

P53

0.99 (0.61–1.60)

0.90

1.10 (0.67–1.82)

0.67

Nuclear pMEK

1.58 (0.93–2.07)

0.09

1.70 (0.95–3.02)

0.07

Cytoplasmic pMEK

0.55 (0.32–0.92)

0.02

0.48 (0.28–0.84)

0.01

  1. Abbreviations: CI confidence interval; DFS disease-free survival; ECOG Eastern Cooperative Oncology Group; HR hazard ratio; OS overall survival